KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$21.6 million.

  • Inovio Pharmaceuticals' Free Cash Flow rose 2114.13% to -$21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.1 million, marking a year-over-year increase of 1987.4%. This contributed to the annual value of -$104.6 million for FY2024, which is 1613.81% up from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Free Cash Flow of -$21.6 million as of Q3 2025, which was up 2114.13% from -$20.8 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Free Cash Flow registered a high of -$19.7 million during Q4 2024, and its lowest value of -$78.7 million during Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was -$32.3 million (2023), whereas its average is -$38.6 million.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Free Cash Flow tumbled by 18935.5% in 2021, and later skyrocketed by 5690.64% in 2023.
  • Inovio Pharmaceuticals' Free Cash Flow (Quarter) stood at -$38.5 million in 2021, then grew by 5.27% to -$36.5 million in 2022, then increased by 28.02% to -$26.3 million in 2023, then rose by 25.16% to -$19.7 million in 2024, then fell by 10.06% to -$21.6 million in 2025.
  • Its last three reported values are -$21.6 million in Q3 2025, -$20.8 million for Q2 2025, and -$26.9 million during Q1 2025.